Chloe Orkin on long-acting cabotegravir

from The Lancet HIV in conversation with · host The Lancet HIV

Professor Chloe Orkin (Queen Mary University London, UK) joins Peter Hayward to talk about long-acting cabotegravir for HIV treatment and the 96 weeks of the FLAIR study. Read the full article: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30340-4/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Mar 29, 2021

Embed this episode

Attribution link and audio player

Ready to play

Chloe Orkin on long-acting cabotegravir

0:00 16:03

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet HIV in conversation with?

This episode is 16 minutes long.

When was this The Lancet HIV in conversation with episode published?

This episode was published on March 29, 2021.

Can I download this The Lancet HIV in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!